Abstract
The relationship between the cytochrome P450 (CYP) 2D6 genotype and the steady-state plasma concentrations (Css) of trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) was studied in 54 depressed Japanese patients receiving trazodone 150 mg at bedtime. By use of allele-specific PCR analysis, the wild type allele, three mutated alleles causing absent enzyme activity (CYP2D6A, CYP2D6B and CYP2D6D) and one mutated allele causing decreased enzyme activity (CYPZD6 Ch) were identified. The means (ranges) of the Css of trazodone, corrected to the median body weight in 17 cases with no mutated allele, 27 cases with one mutated allele and 10 cases with two mutated alleles, were 556 (281–1115), 643 (302–1362) and 671 (234–1418) ng/ml, respectively, while the values of mCPP were 60 (35–121), 65 (33–99) and 58 (38–112) ng/ml, respectively. Neither the Css of trazodone (F = 0.80, P = 0.45) nor that of mCPP (F = 0.49, P = 0.61) significantly differed among the three groups. The present study thus suggests that the CYP2D6 genotype cannot predict the Css of these compounds.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 24 January 1997/Final version: 26 March 1997
Rights and permissions
About this article
Cite this article
Mihara, K., Otani, K., Suzuki, A. et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology 133, 95–98 (1997). https://doi.org/10.1007/s002130050376
Issue Date:
DOI: https://doi.org/10.1007/s002130050376